Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy

NCT04752332 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04752332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04752332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Terminated
Start date
May 10, 2021
Completion date
June 26, 2024
Enrollment
111 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms